Stifel Nicolaus Increases Astera Labs (NASDAQ:ALAB) Price Target to $150.00

Astera Labs (NASDAQ:ALAB) had its price objective boosted by equities researchers at Stifel Nicolaus from $100.00 to $150.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 12.28% from the company’s previous close.

Several other equities analysts have also commented on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $65.00 price target on shares of Astera Labs in a research note on Wednesday, October 9th. Barclays increased their target price on shares of Astera Labs from $70.00 to $87.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Northland Securities cut shares of Astera Labs from an “outperform” rating to a “market perform” rating and boosted their price target for the company from $100.00 to $120.00 in a research report on Thursday, January 2nd. Northland Capmk downgraded shares of Astera Labs from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 2nd. Finally, Roth Mkm lifted their target price on Astera Labs from $80.00 to $105.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Astera Labs currently has a consensus rating of “Moderate Buy” and an average price target of $105.75.

Astera Labs Stock Performance

Shares of ALAB stock opened at $133.60 on Monday. The firm’s 50 day moving average price is $112.23 and its 200-day moving average price is $72.74. Astera Labs has a one year low of $36.22 and a one year high of $147.39.

Astera Labs (NASDAQ:ALAB) last released its earnings results on Monday, November 4th. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.06. Astera Labs had a negative return on equity of 15.57% and a negative net margin of 30.69%. The company had revenue of $113.10 million during the quarter, compared to the consensus estimate of $97.50 million. Astera Labs’s quarterly revenue was up 47.1% on a year-over-year basis. On average, research analysts forecast that Astera Labs will post -0.45 earnings per share for the current year.

Insider Activity at Astera Labs

In related news, Director Jack R. Lazar sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, October 11th. The stock was sold at an average price of $69.95, for a total value of $139,900.00. Following the sale, the director now owns 135,000 shares in the company, valued at $9,443,250. This represents a 1.46 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Michael Truett Tate sold 16,000 shares of the company’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $117.84, for a total value of $1,885,440.00. Following the completion of the sale, the chief financial officer now directly owns 1,412,888 shares in the company, valued at $166,494,721.92. This trade represents a 1.12 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,850,119 shares of company stock worth $178,711,939 over the last 90 days.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ALAB. Strategic Blueprint LLC lifted its position in Astera Labs by 3.6% during the 3rd quarter. Strategic Blueprint LLC now owns 5,684 shares of the company’s stock worth $298,000 after acquiring an additional 195 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Astera Labs by 78.3% in the fourth quarter. GAMMA Investing LLC now owns 510 shares of the company’s stock worth $68,000 after purchasing an additional 224 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Astera Labs by 5.7% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,284 shares of the company’s stock valued at $277,000 after buying an additional 284 shares during the last quarter. Hollencrest Capital Management acquired a new stake in shares of Astera Labs during the 3rd quarter worth approximately $26,000. Finally, Venturi Wealth Management LLC boosted its position in Astera Labs by 26.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 2,400 shares of the company’s stock valued at $126,000 after purchasing an additional 500 shares during the period. 60.47% of the stock is currently owned by hedge funds and other institutional investors.

About Astera Labs

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.